Nevertheless, most of the accumulated research for establishing the role of this molecule as a marker for CSC comes from studies done in brain tumors: CD133 has been found to mark CSC in different types of brain tumors, including glioblastoma multiform (GBM), pediatric medulloblastoma and ependymomas [6,19-22]. The gene discussed is PROM1; the disease is brain neoplasm.